Skip to main content

Table 3 Competing risk analysis of insulin usage effects on dementia by Stepwise adjusting confounders

From: The protective effects of insulin on the developing of dementia in chronic kidney disease patients with hypertension and diabetes: a population-based nationwide study

 

Insulin (users vs. nonusers)

Every incremental of MPR of insulin

HR (95%CI)

p value

HR (95%CI)

p value

Crude

0.628 (0.533–0.741)

< 0.001

0.994 (0.992–0.996)

< 0.001

Model 1

0.631 (0.535–0.744)

< 0.001

0.995 (0.992–0.997)

< 0.001

Model 2

0.636 (0.539–0.751)

< 0.001

0.995 (0.992–0.997)

< 0.001

Model 3

0.652 (0.552–0.771)

< 0.001

0.995 (0.993–0.998)

< 0.001

  1. Model 1 is adjusted for age and gender. Model 2 comprises model 1 as well as adjustments for comorbidities, including ischemic heart disease, hyperlipidemia, diabetes, atrial fibrillation, congestive heart failure, peripheral artery disease, asthma, chronic obstructive pulmonary disease, major depression, Parkinson’s disease, rheumatoid arthritis, insomnia, hyperthyroidism, hypothyroidism, and gout. Model 3 comprises model 2 as well as adjustments for medications of benzodiazepine, anticoagulants, non-steroid anti-inflammatory drug, acetaminophen, statins, calcium channel blocker, angiotensin converting enzyme inhibitors, angiotensin receptor blockades, metformin, beta–blocker, and diuretics
  2. Abbreviation: MPR, medication possession ratio; HR, hazard ratio; CI, confidence interval
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us